ST. LOUIS — Individuals are suing an international pharmaceutical company, citing alleged breach of implied warranty.
Katherine Benjamin, Paul Bolepo, Willie Carmichael, et al. filed a complaint June 19 in the St. Louis 22nd Judicial Circuit Court against Boehringer Ingelheim Pharmaceuticals Inc. and Boehringer Ingelheim International GMBH alleging that the defendant failed to warn physicians and consumers of the risks associated with the use of Pradaxa.
According to the complaint, the plaintiffs allege that in October 2010, the Food & Drug Administration approved Pradaxa as an oral anticoagulant to reduce the risk of stroke and systematic embolism in adults with non-valvular atrial fibrillation. The plaintiffs claim the product has harmful effects that were never disclosed to physicians and patients. As a result, the plaintiffs say they have suffered injuries that led to untimely death to some patients.
The plaintiffs hold Boehringer Ingelheim Pharmaceuticals and Boehringer Ingelheim International responsible because the defendant allegedly failed to provide appropriate warnings and instructions about the dangers posed by Pradaxa, failed to conduct adequate safety and efficacy studies before marketing the product and failed to design a product that was not capable of causing personal injuries and death.
The plaintiffs request a trial by jury and seek judgment for general, compensatory and punitive damages, costs of action, and such further relief the Court deems just and appropriate. They are represented by Jeffery J. Lowe, John F. Garvey Jr., Sarah Shoemake Doles and Alyson M. Perick of Carey Danis & Lowe in Clayton and Michael T. Gallagher of The Gallagher Law Firm LLP in Houston.
St. Louis 22nd Judicial Circuit Court case number 1722-CC10608